Equities Analysts Issue Forecasts for Triumph Bancorp Inc’s Q2 2019 Earnings (NASDAQ:TBK)

Triumph Bancorp Inc (NASDAQ:TBK) – Equities research analysts at B. Riley cut their Q2 2019 earnings per share estimates for shares of Triumph Bancorp in a report released on Thursday, July 11th. B. Riley analyst S. Moss now anticipates that the financial services provider will earn $0.44 per share for the quarter, down from their prior forecast of $0.50. B. Riley has a “Buy” rating and a $33.00 price target on the stock. B. Riley also issued estimates for Triumph Bancorp’s Q3 2019 earnings at $0.61 EPS, Q4 2019 earnings at $0.74 EPS, FY2019 earnings at $2.34 EPS, Q1 2020 earnings at $0.58 EPS, Q2 2020 earnings at $0.68 EPS, Q3 2020 earnings at $0.79 EPS, Q4 2020 earnings at $0.90 EPS and FY2020 earnings at $2.95 EPS.

Triumph Bancorp (NASDAQ:TBK) last announced its quarterly earnings data on Wednesday, April 17th. The financial services provider reported $0.55 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.03. Triumph Bancorp had a return on equity of 9.61% and a net margin of 17.70%. The business had revenue of $68.85 million during the quarter, compared to analyst estimates of $70.32 million. During the same quarter in the prior year, the firm posted $0.52 earnings per share.

Several other brokerages also recently issued reports on TBK. Zacks Investment Research raised Vistra Energy from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Saturday. Stephens assumed coverage on LiqTech International in a research note on Tuesday, July 9th. They issued an “overweight” rating and a $13.00 price objective for the company. ValuEngine downgraded Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. BidaskClub downgraded Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, June 26th. Finally, Piper Jaffray Companies set a $15.00 price objective on BioCryst Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, April 22nd. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. Triumph Bancorp has an average rating of “Hold” and an average target price of $41.20.

Shares of NASDAQ TBK opened at $28.47 on Friday. Triumph Bancorp has a 12 month low of $27.21 and a 12 month high of $44.70. The stock has a market capitalization of $758.70 million, a P/E ratio of 12.88, a price-to-earnings-growth ratio of 1.25 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.00 and a current ratio of 1.00. The company’s fifty day moving average is $28.95.

In related news, Director Michael P. Rafferty acquired 1,500 shares of the stock in a transaction dated Wednesday, May 15th. The shares were acquired at an average price of $29.25 per share, with a total value of $43,875.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Robert Dobrient acquired 1,000 shares of the stock in a transaction dated Tuesday, June 11th. The shares were bought at an average cost of $28.76 per share, for a total transaction of $28,760.00. Following the acquisition, the director now owns 64,282 shares in the company, valued at approximately $1,848,750.32. The disclosure for this purchase can be found here. In the last three months, insiders have bought 9,228 shares of company stock worth $270,043. 8.54% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Banc Funds Co. LLC grew its holdings in Triumph Bancorp by 10.4% in the 1st quarter. Banc Funds Co. LLC now owns 403,300 shares of the financial services provider’s stock valued at $11,853,000 after buying an additional 38,000 shares during the last quarter. Great West Life Assurance Co. Can grew its holdings in Triumph Bancorp by 12.0% in the 4th quarter. Great West Life Assurance Co. Can now owns 33,004 shares of the financial services provider’s stock valued at $903,000 after buying an additional 3,532 shares during the last quarter. Metropolitan Life Insurance Co. NY grew its holdings in Triumph Bancorp by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,958 shares of the financial services provider’s stock valued at $236,000 after buying an additional 6,215 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in Triumph Bancorp by 476.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 887 shares of the financial services provider’s stock valued at $27,000 after buying an additional 733 shares during the last quarter. Finally, BlackRock Inc. grew its holdings in Triumph Bancorp by 2.4% in the 4th quarter. BlackRock Inc. now owns 3,588,809 shares of the financial services provider’s stock valued at $106,588,000 after buying an additional 83,458 shares during the last quarter. 78.63% of the stock is currently owned by hedge funds and other institutional investors.

Triumph Bancorp Company Profile

Triumph Bancorp, Inc operates as a financial holding company for TBK Bank, SSB that provides banking and commercial finance products and services to retail customers and small-to-mid-sized businesses in the United States. The company operates through Banking, Factoring, and Corporate segments. It offers depository products, including checking, savings, and money market accounts, as well as certificates of deposit; and commercial and industrial loans, loans to purchase capital equipment, and business loans for working capital and operational purposes.

Read More: How to interpret Moving Average Convergence Divergence (MACD)

Earnings History and Estimates for Triumph Bancorp (NASDAQ:TBK)

Receive News & Ratings for Triumph Bancorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Triumph Bancorp and related companies with MarketBeat.com's FREE daily email newsletter.